UniQure Set to Reveal Promising Four-Year Results for Huntington's Gene Therapy
By Editor • September 10, 2026 • 1 min read
UniQure is on the verge of unveiling the four-year outcomes from its pivotal clinical trial for AMT-130, a groundbreaking gene therapy aimed at treating Huntington's disease. The announcement is anticipated before the end of September, capturing the attention of the biotech community and potential stakeholders.
Last year, the company released three-year data showing that a high dose of AMT-130, given to 12 patients, effectively slowed Huntington's disease progression by an impressive 75% when compared to a control group drawn from a comprehensive natural history study. This initial finding has set high expectations for the upcoming results, which could further validate the therapy's efficacy.
As the biotech field eagerly awaits these results, the implications of AMT-130 could be significant for patients battling Huntington's disease and for UniQure's future in the competitive gene therapy landscape.
Source: www.statnews.com
#AMT-130 #clinical trial #gene therapy #Huntington's disease #UniQure
